VRDN
Viridian Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | -12 | 71.65M | $1.32B | +6 | −18 |
| Q1 2026 | 88 | +7 | 66.96M | $1.32B | +11 | −5 |
| Q4 2025 | 82 | +2 | 62.58M | $1.95B | +4 | −1 |
| Q3 2025 | 16 | -1 | 34.97M | $754.70M | — | −1 |
| Q2 2025 | 14 | -2 | 33.44M | $467.46M | — | −2 |
| Q1 2025 | 13 | +2 | 10.47M | $141.20M | +2 | — |
| Q4 2024 | 11 | -2 | 10.88M | $208.63M | — | −2 |
| Q3 2024 | 12 | +3 | 5.78M | $131.57M | +3 | — |
| Q2 2024 | 9 | — | 3.15M | $40.97M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.41M | — | $18.36M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.41M | — | $18.36M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 419.82K | — | $5.46M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 395.50K | — | $5.15M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 284.04K | — | $3.70M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 284.04K | — | $3.70M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 284.04K | — | $3.70M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 284.04K | — | $3.70M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 247.60K | — | $3.22M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 228.18K | — | $2.97M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 72.97K | — | $949,392 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 44.67K | — | $581,170 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 44.67K | — | $581,170 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 44.42K | — | $578,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 111.32M shares, $2.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.21K sh · $103,194
Officer · 10.00K sh · $245,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology